PULM Pulmatrix, Inc.

-0.14  -5%
Previous Close 2.64
Open 2.68
Price To book 3.07
Market Cap 47.81M
Shares 19,122,000
Volume 267,647
Short Ratio 1.80
Av. Daily Volume 1,382,390

SEC filingsSee all SEC filings

  1. 8-K - Current report 17913766
  2. 8-K - Current report 17908030
  3. 8-K - Current report 17903326
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17816371
  5. 8-K - Current report 17816313

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2017.

Latest News

  1. Innovative Pulmatrix Drug Offers New Hope for Fighting Fungal Lung Infections
  2. Amit D. Munshi Joins Pulmatrix's Board of Directors
  3. Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.
  4. Zacks Initiates on Pulmatrix (NASDAQ:PULM)
  5. Today's Research Reports on Biotech Stocks to Watch: Pulmatrix and Puma Biotechnology
  6. Pulmatrix's Unique Inhaled Drug Candidate Has "Blockbuster" Potential, Says CFO Bill Duke
  7. Pulmatrix Receives Key US Patent for its Inhaled Drug for COPD
  8. Pulmatrix Reports Q1 2017 Financial Results
  9. Pulmatrix Appoints Ted Raad, MBA, as Chief Business Officer
  10. Today's Research Reports on Biotech Stocks to Watch: TherapeuticsMD and Pulmatrix
  11. Q1 Roundup: Winners and Losers of Biotech Sector
  12. Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board
  13. Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine
  14. Pulmatrix Inhaled Drug Delivery Tech Gets EU Patent
  15. Why Pulmatrix Investors Are Breathing a Sigh of Relief
  16. Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology
  17. Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
  18. Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline
  19. Explaining Innovative Drug Technologies Through Animation
  20. Penny Stocks to Watch for March 2017 (MOBL)